These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 26898828)

  • 1. Regulation of BRAF protein stability by a negative feedback loop involving the MEK-ERK pathway but not the FBXW7 tumour suppressor.
    Hernandez MA; Patel B; Hey F; Giblett S; Davis H; Pritchard C
    Cell Signal; 2016 Jun; 28(6):561-71. PubMed ID: 26898828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
    Joseph EW; Pratilas CA; Poulikakos PI; Tadi M; Wang W; Taylor BS; Halilovic E; Persaud Y; Xing F; Viale A; Tsai J; Chapman PB; Bollag G; Solit DB; Rosen N
    Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14903-8. PubMed ID: 20668238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
    Poulikakos PI; Zhang C; Bollag G; Shokat KM; Rosen N
    Nature; 2010 Mar; 464(7287):427-30. PubMed ID: 20179705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway.
    Pratilas CA; Taylor BS; Ye Q; Viale A; Sander C; Solit DB; Rosen N
    Proc Natl Acad Sci U S A; 2009 Mar; 106(11):4519-24. PubMed ID: 19251651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SEL-10/Fbw7-dependent negative feedback regulation of LIN-45/Braf signaling in C. elegans via a conserved phosphodegron.
    de la Cova C; Greenwald I
    Genes Dev; 2012 Nov; 26(22):2524-35. PubMed ID: 23154983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
    Lee MH; Lee SE; Kim DW; Ryu MJ; Kim SJ; Kim SJ; Kim YK; Park JH; Kweon GR; Kim JM; Lee JU; De Falco V; Jo YS; Shong M
    J Clin Endocrinol Metab; 2011 Jan; 96(1):E19-30. PubMed ID: 20926530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.
    Friday BB; Yu C; Dy GK; Smith PD; Wang L; Thibodeau SN; Adjei AA
    Cancer Res; 2008 Aug; 68(15):6145-53. PubMed ID: 18676837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An NKX2-1/ERK/WNT feedback loop modulates gastric identity and response to targeted therapy in lung adenocarcinoma.
    Zewdu R; Mehrabad EM; Ingram K; Fang P; Gillis KL; Camolotto SA; Orstad G; Jones A; Mendoza MC; Spike BT; Snyder EL
    Elife; 2021 Apr; 10():. PubMed ID: 33821796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers.
    Kotani H; Adachi Y; Kitai H; Tomida S; Bando H; Faber AC; Yoshino T; Voon DC; Yano S; Ebi H
    Oncogene; 2018 Mar; 37(13):1775-1787. PubMed ID: 29348459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma.
    Packer LM; East P; Reis-Filho JS; Marais R
    Pigment Cell Melanoma Res; 2009 Dec; 22(6):785-98. PubMed ID: 19682280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
    Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
    Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
    Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fbxw7 contributes to tumor suppression by targeting multiple proteins for ubiquitin-dependent degradation.
    Fujii Y; Yada M; Nishiyama M; Kamura T; Takahashi H; Tsunematsu R; Susaki E; Nakagawa T; Matsumoto A; Nakayama KI
    Cancer Sci; 2006 Aug; 97(8):729-36. PubMed ID: 16863506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
    Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
    Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant.
    Nakai C; Mimaki S; Matsushima K; Shinozaki E; Yamazaki K; Muro K; Yamaguchi K; Nishina T; Yuki S; Shitara K; Bando H; Suzuki Y; Akagi K; Nomura S; Fujii S; Sugiyama M; Nishida N; Mizokami M; Koh Y; Koshizaka T; Okada H; Abe Y; Ohtsu A; Yoshino T; Tsuchihara K
    Int J Clin Oncol; 2023 May; 28(5):654-663. PubMed ID: 36856908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationships among
    Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
    World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.
    Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD
    J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. F-box and WD repeat domain-containing-7 (Fbxw7) protein targets endoplasmic reticulum-anchored osteogenic and chondrogenic transcriptional factors for degradation.
    Yumimoto K; Matsumoto M; Onoyama I; Imaizumi K; Nakayama KI
    J Biol Chem; 2013 Oct; 288(40):28488-502. PubMed ID: 23955342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SCF
    Sugiyama S; Yumimoto K; Inoue I; Nakayama KI
    Genes Cells; 2019 May; 24(5):354-365. PubMed ID: 30838725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.
    Mitsiades CS; Negri J; McMullan C; McMillin DW; Sozopoulos E; Fanourakis G; Voutsinas G; Tseleni-Balafouta S; Poulaki V; Batt D; Mitsiades N
    Mol Cancer Ther; 2007 Mar; 6(3):1070-8. PubMed ID: 17363500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.